This database contains 350 studies, archived under the term: "therapeutic use"
Click here to filter this large number of results.
Vitamin D and risk of cognitive decline in elderly persons
Llewellyn, David J.,
Lang, Iain A.,
Langa, Kenneth M.,
Muniz-Terrera, Graciela,
Phillips, Caroline L.,
Cherubini, Antonio,
Ferrucci, Luigi,
Melzer, David
Background: To our knowledge, no prospective study has examined the association between vitamin D and cognitive decline or dementia.; Methods: We determined whether low levels of serum 25-hydroxyvitamin D (25[OH]D) were associated with an increased risk of substantial cognitive decline in the InCHIANTI population-based study conducted in Italy between 1998 and 2006 with follow-up assessments […]
DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer’s disease – a multicentre RCT
Jones, Rob,
Sheehan, Bart,
Phillips, Patrick,
Juszczak, Ed,
Adams, Jessica,
Baldwin, Ashley,
Ballard, Clive,
Banerjee, Sube,
Barber, Bob,
Bentham, Peter,
Brown, Richard,
Burns, Alistair,
Dening, Tom,
Findlay, David,
Gray, Richard,
Griffin, Mary,
Holmes, Clive,
Hughes, Alan,
Jacoby, Robin,
Johnson, Tony,
Jones, Roy,
Knapp, Martin,
Lindesay, James,
McKeith, Ian,
McShane, Rupert,
Macharouthu, Ajay,
O'Brien, John,
Onions, Caroline,
Passmore, Peter,
Raftery, James,
Ritchie, Craig,
Howard, Rob
Background: Alzheimer’s disease (AD) is the commonest cause of dementia. Cholinesterase inhibitors, such as donepezil, are the drug class with the best evidence of efficacy, licensed for mild to moderate AD, while the glutamate antagonist memantine has been widely prescribed, often in the later stages of AD. Memantine is licensed for moderate to severe dementia […]
Akatinol memantine in patients with vascular cognitive disorders
Treatment of cognitive disorders developed in cerebrovascular pathology is an actual medical problem. Of great importance is the timed diagnosis of these changes in the earlier phases of the development of cognitive deficit as well as adequate therapy that can delay and prevent the development of such complication as dementia. Pathogenetic mechanisms of cognitive disorders […]
Effects of atorfastatin on the cognitive function of patients with vascular cognitive impairment and different apolipoprotein E genotypes
Gu, Ping,
Wang, Jian,
Shao, Jia-qing,
Du, Hong,
Zhang, Kai,
Jiang, Wei-min
Objective: To study the effect of atorfastatin on the cognitive function of patients with vascular cognitive impairment (VCI) and different apolipoprotein E genotypes.; Methods: The ApoE polymorphism was genotyped by PCR sequencing and the patients were divided into Eepsilon4 carrier (epsilon4+) group (n=24) and epsilon4- group (n=51). All the patients were given 20 mg oral […]
Clinical stabilisation in neurodegenerative diseases: clinical study in phase II
Introduction: Neurodegenerative disorders, such as Parkinson’s disease (PD), Alzheimer’s disease (AD) and multiple sclerosis (MS), are progressive pathological conditions in which current treatments have not proved to be effective at curbing their progress (clinical stabilisation). Although they have very different clinical characteristics, they share the same pathophysiological mechanisms of progression. We developed a compound designed […]
Efficacy of acatinol memantine in mild cognitive disorder
An open 6 month clinical trial of efficacy of acatinol has been carried out in patients with mild cognitive disorder (MCD). Forty patients received acatinol and 20 patients of comparison group were treated with piracetam. Mean age of patients was 67,7+/-7,2 years. Patient’s state was assessed with a battery of scales, questionnaires and neuropsychological tests. […]
Galantamine (reminyl) in the treatment of severe Alzheimer’s disease
Twenty-five patients with Alzheimer’s disease (AD) in moderate-severe and severe stages received galantamine in dosage 8 mg daily during the 1st month with the following increasing to 16 mg daily. Six patients received 24 mg per day from the 3rd month. The total duration of therapy was 26 weeks. 15 patients received in addition the […]